問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Thoracic Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

張山岳
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張山岳

List

57Cases

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Subcutaneous injections

Participate Sites
6Sites

Recruiting6Sites

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    Pembrolizumab (MK-3475) / 商品名：KEYTRUDA/吉舒達

Participate Sites
7Sites

Recruiting4Sites

Terminated1Sites

2021-03-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2021-12-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-03-01 - 2026-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2019-12-01 - 2024-12-31

Phase II

Completed
A Phase II, two arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)

  • Condition/Disease

    non-small cell lung cancer(NSCLC)

  • Test Drug

    Tepotinib

Participate Sites
7Sites

Recruiting7Sites

2018-07-18 - 2021-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2025-01-01 - 2028-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-08-01 - 2028-11-05

Phase II

Completed
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Solution

Participate Sites
5Sites

Recruiting5Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    injection

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB